| 
																	
																	
																		 Connection
 
																		 Co-Authors
																		
																	 
																		This is a "connection" page, showing publications co-authored by   Andrew Donson   and   Ilango Balakrishnan.    
																		
																	 
																			
																					
					
					
		
			
			
			|  | 
				
					|  | Connection Strength |  |  
					|  |   |  |  
					|  | 0.864 |  |  |  |  
		
		
			
				Balakrishnan I, Madhavan K, Pierce A, Michlin J, Brunt B, Lakshmanachetty S, Wang D, DeSisto J, Nuss ZJ, Davidson N, Walker F, Suresh A, Donson A, Sanford B, Jones KL, Danis EP, Mitra SS, Green AL, Dahl N, Vibhakar R, Venkataraman S. Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma. Cancer Res. 2025 May 27.	
				
				
					Score: 0.243
				
				Balakrishnan I, Danis E, Pierce A, Madhavan K, Wang D, Dahl N, Sanford B, Birks DK, Davidson N, Metselaar DS, Meel MH, Lemma R, Donson A, Vijmasi T, Katagi H, Sola I, Fosmire S, Alimova I, Steiner J, Gilani A, Hulleman E, Serkova NJ, Hashizume R, Hawkins C, Carcaboso AM, Gupta N, Monje M, Jabado N, Jones K, Foreman N, Green A, Vibhakar R, Venkataraman S. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Rep. 2020 10 20; 33(3):108286.	
				
				
					Score: 0.176
				
				Lakshmanachetty S, Riemondy K, Sanford B, Donson A, Chen V, Balakrishnan I, Prince EW, Hankinson T, Dahl N, Vibhakar R, Foreman N, Venkatraman S, Mitra SS. Differential phagocytosis induces diverse macrophage activation states in malignant gliomas. J Immunother Cancer. 2025 Sep 05; 13(9).	
				
				
					Score: 0.062
				
				Alimova I, Wang D, DeSisto J, Danis E, Lakshmanachetty S, Prince E, Murdock G, Pierce A, Donson A, Balakrishnan I, Serkova N, Lin H, Foreman NK, Dahl N, Venkataraman S, Vibhakar R. SIRT2 Regulates the SMARCB1 Loss-Driven Differentiation Block in ATRT. Mol Cancer Res. 2025 Jun 03; 23(6):515-529.	
				
				
					Score: 0.061
				
				Lakshmanachetty S, Riemondy K, Sanford B, Donson A, Balakrishnan I, Prince E, Hankinson T, Dahl N, Vibhakar R, Foreman NK, Venkataraman S, Mitra SS. Differential Phagocytosis induces Diverse Macrophage Activation States in Malignant Gliomas. bioRxiv. 2025 Mar 17.	
				
				
					Score: 0.060
				
				Wang D, Veo B, Pierce A, Fosmire S, Madhavan K, Balakrishnan I, Donson A, Alimova I, Sullivan KD, Joshi M, Erlander M, Ridinger M, Foreman NK, Venkataraman S, Vibhakar R. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro Oncol. 2022 03 12; 24(3):414-426.	
				
				
					Score: 0.049
				
				Alimova I, Wang D, Danis E, Pierce A, Donson A, Serkova N, Madhavan K, Lakshmanachetty S, Balakrishnan I, Foreman NK, Mitra S, Venkataraman S, Vibhakar R. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. Int J Oncol. 2022 Mar; 60(3).	
				
				
					Score: 0.048
				
				Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor. Oncotarget. 2017 Nov 14; 8(57):97290-97303.	
				
				
					Score: 0.036
				
				Griesinger AM, Witt DA, Grob ST, Georgio Westover SR, Donson AM, Sanford B, Mulcahy Levy JM, Wong R, Moreira DC, DeSisto JA, Balakrishnan I, Hoffman LM, Handler MH, Jones KL, Vibhakar R, Venkataraman S, Foreman NK. NF-?B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. Neuro Oncol. 2017 Oct 01; 19(10):1350-1360.	
				
				
					Score: 0.036
				
				Amani V, Prince EW, Alimova I, Balakrishnan I, Birks D, Donson AM, Harris P, Levy JM, Handler M, Foreman NK, Venkataraman S, Vibhakar R. Polo-like Kinase?1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. BMC Cancer. 2016 08 18; 16:647.	
				
				
					Score: 0.033
				
				Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R. Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget. 2016 Aug 16; 7(33):53881-53894.	
				
				
					Score: 0.033
				
				Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer. 2014 Mar 24; 13:72.	
				
				
					Score: 0.028
				 | 
																	
																		
																			
																					       Connection Strength       
  The connection strength for concepts is the sum of the scores for each matching publication.    
 Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
 |